A multicentre, multinational, randomized, placebo‐controlled, double‐blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin ( <scp>LC15</scp> ‐0444) in patients with type 2 diabetes - Concepedia

Concepedia

Publication | Closed Access

A multicentre, multinational, randomized, placebo‐controlled, double‐blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin ( <scp>LC15</scp> ‐0444) in patients with type 2 diabetes

50

Citations

8

References

2012

Year

Sae Jeong Yang, Kyong Wan Min, Sandeep K. Gupta, J. Y. Park, Vyankatesh Shivane, Shailesh Pitale, Pankaj Kumar Agarwal, Aravind Sosale, Pramod Gandhi, Mala Dharmalingam,

Diabetes Obesity and Metabolism

Abstract

This study showed the efficacy and safety of gemigliptin 50 mg administered once daily as a monotherapy for type 2 diabetes patients.

References

	Year	Citations

Page 1